|
JPH0515775Y2
(https=)
|
1987-07-13 |
1993-04-26 |
|
|
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
PT1107964E
(pt)
|
1998-08-11 |
2010-06-11 |
Novartis Ag |
Derivados de isoquinolina com actividade inibidora da angiogénese
|
|
US6133031A
(en)
|
1999-08-19 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of focal adhesion kinase expression
|
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
KR100786927B1
(ko)
|
2000-06-28 |
2007-12-17 |
스미스클라인비이참피이엘시이 |
습식 분쇄방법
|
|
BR0212760A
(pt)
|
2001-09-19 |
2004-12-07 |
Aventis Pharma Sa |
Compostos quìmicos
|
|
DE60213842T2
(de)
|
2001-10-30 |
2007-09-06 |
Novartis Ag |
Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
|
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
TWI335913B
(en)
|
2002-11-15 |
2011-01-11 |
Vertex Pharma |
Diaminotriazoles useful as inhibitors of protein kinases
|
|
UA80767C2
(en)
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
AR045944A1
(es)
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
|
US20060106020A1
(en)
|
2004-04-28 |
2006-05-18 |
Rodgers James D |
Tetracyclic inhibitors of Janus kinases
|
|
AU2005309019A1
(en)
|
2004-11-24 |
2006-06-01 |
Novartis Ag |
Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
CA2673038C
(en)
|
2006-12-22 |
2015-12-15 |
Incyte Corporation |
Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
KR20150036210A
(ko)
|
2007-06-13 |
2015-04-07 |
인사이트 코포레이션 |
야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
|
|
UA104849C2
(uk)
|
2007-11-16 |
2014-03-25 |
Інсайт Корпорейшн |
4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
|
|
HUE029767T2
(en)
|
2008-03-11 |
2017-04-28 |
Incyte Holdings Corp |
JAK inhibitor azetidine and cyclobutane derivatives
|
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
TWI720517B
(zh)
|
2009-01-15 |
2021-03-01 |
美商英塞特公司 |
製造ｊａｋ抑制劑之方法及相關中間化合物
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
SI2432472T1
(sl)
|
2009-05-22 |
2019-11-29 |
Incyte Holdings Corp |
3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
EA021478B1
(ru)
|
2009-10-09 |
2015-06-30 |
Инсайт Корпорейшн |
ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
|
|
JP5858434B2
(ja)
|
2010-02-18 |
2016-02-10 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
|
|
EP3354652B1
(en)
|
2010-03-10 |
2020-05-06 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
KR20130094710A
(ko)
|
2010-04-14 |
2013-08-26 |
어레이 바이오파마 인크. |
Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
|
|
PE20130216A1
(es)
|
2010-05-21 |
2013-02-27 |
Incyte Corp |
Formulacion topica para un inhibidor de jak
|
|
JOP20190250A1
(ar)
|
2010-07-14 |
2017-06-16 |
Regeneron Pharma |
صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
PE20140146A1
(es)
|
2010-11-19 |
2014-02-06 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
|
WO2012076063A1
(en)
|
2010-12-10 |
2012-06-14 |
Rottapharm S.P.A. |
Pyridine amide derivatives as ep4 receptor antagonists
|
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
|
WO2012116248A1
(en)
|
2011-02-24 |
2012-08-30 |
Massachusetts Institute Of Technology |
ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
|
|
CN103797010B
(zh)
|
2011-06-20 |
2016-02-24 |
因塞特控股公司 |
作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
|
|
EP2741747A1
(en)
|
2011-08-10 |
2014-06-18 |
Novartis Pharma AG |
JAK P13K/mTOR COMBINATION THERAPY
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
CA2849168A1
(en)
|
2011-09-22 |
2013-03-28 |
Merck Sharp & Dohme Corp. |
Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
TWI646099B
(zh)
|
2012-11-01 |
2019-01-01 |
英塞特控股公司 |
作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
|
|
PH12020551186B1
(en)
|
2012-11-15 |
2024-03-20 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
RS62867B1
(sr)
|
2013-03-06 |
2022-02-28 |
Incyte Holdings Corp |
Postupci i intermedijeri za dobijanje inhibitora jak
|
|
TWI733288B
(zh)
|
2013-05-17 |
2021-07-11 |
愛爾蘭商健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
US9371282B2
(en)
|
2013-05-17 |
2016-06-21 |
Centrexion Therapeutics Corporation |
Somatostatin receptor subtype 4 (SSTR4) agonists
|
|
BR112015028873A2
(pt)
|
2013-05-17 |
2017-07-25 |
Hoffmann La Roche |
heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b
|
|
EP2803668A1
(en)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
|
|
HUE033587T2
(hu)
|
2013-05-17 |
2017-12-28 |
Incyte Corp |
Bipirazol-származékok mint JAK inhibitorok
|
|
SMT202000315T1
(it)
|
2013-08-07 |
2020-07-08 |
Incyte Corp |
Forme di dosaggio a rilascio prolungato per un inibitore di jak1
|
|
CA2921568A1
(en)
|
2013-08-20 |
2015-02-25 |
Incyte Corporation |
Survival benefit in patients with solid tumors with elevated c-reactive protein levels
|
|
AU2014339897A1
(en)
*
|
2013-10-24 |
2016-04-21 |
Abbvie Inc. |
JAK1 selective inhibitor and uses thereof
|
|
KR20160136323A
(ko)
|
2014-02-28 |
2016-11-29 |
인사이트 코포레이션 |
골수형성이상증후군 치료용 jak1 억제제
|
|
MA39987A
(fr)
|
2014-04-30 |
2017-03-08 |
Incyte Corp |
Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
DK3233843T3
(da)
|
2014-12-16 |
2019-11-18 |
Novartis Ag |
Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
|
|
US11815514B2
(en)
|
2015-12-04 |
2023-11-14 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
MX2018011480A
(es)
|
2016-03-22 |
2019-03-28 |
Seattle Children´S Hospital Dba Seattle Children´S Res Institute |
Metodos de intervencion temprana para prevenir o aminorar toxicidad.
|
|
SG11201900344YA
(en)
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
US20190060311A1
(en)
*
|
2017-08-24 |
2019-02-28 |
Aclaris Therapeutics, Inc. |
Compositions and methods for treatment of vitiligo
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
SG11202007164UA
(en)
|
2018-01-30 |
2020-08-28 |
Incyte Corp |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
KR102925957B1
(ko)
|
2018-02-16 |
2026-02-11 |
인사이트 코포레이션 |
사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
|
|
MA52655A
(fr)
|
2018-03-30 |
2021-02-17 |
Incyte Corp |
Biomarqueurs pour maladie cutanée inflammatoire
|
|
SMT202400306T1
(it)
|
2018-03-30 |
2024-09-16 |
Incyte Corp |
Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
|
|
CA3097025A1
(en)
|
2018-04-13 |
2019-10-17 |
Incyte Corporation |
Biomarkers for graft-versus-host disease
|
|
US11624751B2
(en)
*
|
2019-03-19 |
2023-04-11 |
Incyte Corporation |
Biomarkers for vitiligo
|
|
MX2022015221A
(es)
|
2020-06-02 |
2023-03-08 |
Incyte Corp |
Procesos para preparar un inhibidor de cinasa jano 1 (jak1).
|
|
HUE071614T2
(hu)
|
2020-12-04 |
2025-09-28 |
Incyte Corp |
JAK-inhibitor D-vitamin-analóggal bõrbetegségek kezelésére
|
|
UA129643C2
(uk)
|
2021-05-03 |
2025-06-18 |
Інсайт Корпорейшн |
Інгібітори шляху jak1 для лікування вузлуватого свербця
|